Literature DB >> 15835912

The catalytically active serine protease domain of human complement factor I.

Stefanos A Tsiftsoglou1, Antony C Willis, Pengyun Li, Xuehui Chen, Daniel A Mitchell, Zihe Rao, Robert B Sim.   

Abstract

Factor I (fI) is a major regulator of complement. As a protease it has very restricted specificity, cleaving only C3b or C4b in the presence of a cofactor such as factor H (fH). Cleavage of C3b by fI yields iC3b, a major opsonin. The cleavage occurs through the formation of a ternary complex between the enzyme, the substrate, and the cofactor. The catalytic subunit of fI, the SP domain, accommodates substrate recognition and cleavage. The role of the fI heavy chain within the catalysis complex is unknown. Using partial proteolysis and affinity chromatography an intact form of the SP domain was generated and isolated from fI in high yield. fI and the SP domain were found to have similar amidolytic activities but strikingly different proteolytic activities on C3(NH(3)). fI did not cleave C3(NH(3)) in the absence of fH, while in its presence it cleaved C3(NH(3)) rapidly at two sites. The SP domain, however, slowly cleaved C3(NH(3)) in the absence of fH, at more than two sites. Cleavage by the SP domain was inhibited, not stimulated, by fH. Pefabloc SC and antipain inhibited the proteolytic activity of both fI and the SP domain, but suramin inhibited only fI and not the SP domain. The contrast in the proteolytic activities suggests that the heavy chain domains and the cofactor must have roles in orienting the natural substrates and restricting cleavage to the two sites which yield iC3b through a highly specific catalysis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15835912     DOI: 10.1021/bi047680t

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  14 in total

1.  Tag SNPs of CFI contributed to the susceptibility for non-small cell lung cancer in Chinese population.

Authors:  Yingwen Liu; Yanghui Bi; Jia Lin; Lei Cao; Bing He; Zhi Zhang; Yongping Cui; Xuemei Zhang
Journal:  Tumour Biol       Date:  2014-11-15

2.  Analysis of binding sites on complement factor I that are required for its activity.

Authors:  Sara C Nilsson; Izabela Nita; Lisa Månsson; Tom W L Groeneveld; Leendert A Trouw; Bruno O Villoutreix; Anna M Blom
Journal:  J Biol Chem       Date:  2009-12-31       Impact factor: 5.157

3.  Microarray analysis identifies changes in inflammatory gene expression in response to amyloid-beta stimulation of cultured human retinal pigment epithelial cells.

Authors:  Khaliq H Kurji; Jing Z Cui; Tony Lin; David Harriman; Shiv S Prasad; Ljuba Kojic; Joanne A Matsubara
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-09-24       Impact factor: 4.799

4.  Early Versus Late Diagnosis of Complement Factor I Deficiency: Clinical Consequences Illustrated in Two Families with Novel Homozygous CFI Mutations.

Authors:  Clara Franco-Jarava; Elena Álvarez de la Campa; Xavier Solanich; Francisco Morandeira-Rego; Virgínia Mas-Bosch; Marina García-Prat; Xavier de la Cruz; Andrea Martín-Nalda; Pere Soler-Palacín; Manuel Hernández-González; Roger Colobran
Journal:  J Clin Immunol       Date:  2017-09-23       Impact factor: 8.317

Review 5.  100 Years of Suramin.

Authors:  Natalie Wiedemar; Dennis A Hauser; Pascal Mäser
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

6.  A missense mutation in factor I (IF) predisposes to atypical haemolytic uraemic syndrome.

Authors:  Joyce Geelen; Koen van den Dries; Anja Roos; Nicole van de Kar; Corrie de Kat Angelino; Ina Klasen; Leo Monnens; Lambertus van den Heuvel
Journal:  Pediatr Nephrol       Date:  2006-11-15       Impact factor: 3.714

7.  Structural basis for complement factor I control and its disease-associated sequence polymorphisms.

Authors:  Pietro Roversi; Steven Johnson; Joseph J E Caesar; Florence McLean; Kirstin J Leath; Stefanos A Tsiftsoglou; B Paul Morgan; Claire L Harris; Robert B Sim; Susan M Lea
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-18       Impact factor: 11.205

8.  Generation of anaphylatoxins by human beta-tryptase from C3, C4, and C5.

Authors:  Yoshihiro Fukuoka; Han-Zhang Xia; Laura B Sanchez-Muñoz; Anthony L Dellinger; Luis Escribano; Lawrence B Schwartz
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

9.  Streptococcus pyogenes Employs Strain-dependent Mechanisms of C3b Inactivation to Inhibit Phagocytosis and Killing of Bacteria.

Authors:  Garima Agrahari; Zhong Liang; Kristofor Glinton; Shaun W Lee; Victoria A Ploplis; Francis J Castellino
Journal:  J Biol Chem       Date:  2016-03-04       Impact factor: 5.157

10.  Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses.

Authors:  Xiaoguang Xue; Jin Wu; Daniel Ricklin; Federico Forneris; Patrizia Di Crescenzio; Christoph Q Schmidt; Joke Granneman; Thomas H Sharp; John D Lambris; Piet Gros
Journal:  Nat Struct Mol Biol       Date:  2017-07-03       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.